Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease

被引：13

作者：

Burt, RK ^{[1
]}

Brenner, M

Burns, W

Courier, E

Firestein, G

Hahn, B

Heslop, H

Link, C

McFarland, H

Roland, M

Territo, M

Tsokos, G

Traynor, A

机构：

[1] Northwestern Univ, Med Ctr, Chicago, IL 60611 USA

[2] Rupert H Lurie Canc Ctr, Chicago, IL 60611 USA

[3] Baylor Coll Med, Cell & Gene Therapy Ctr, Houston, TX 77030 USA

[4] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[5] Univ Calif San Diego, San Diego, CA 92103 USA

[6] Univ Calif Los Angeles, Los Angeles, CA USA

[7] Human Gene Therapy Res Inst, Des Moines, IA USA

[8] NIH, Bethesda, MD 20892 USA

[9] Henry M Jackson Fdn Advancement Mil Sci, Rockville, MD USA

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2000年 / 20卷 / 01期

关键词：

hematopoietic stem cell transplantation; gene-marked autologous stem cells; autoimmune disease;

D O I：

10.1023/A:1006673408343

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In phase I(safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.

引用

页码：1 / 9

页数：9

共 42 条

[21]

INGHIRAMI G, 1988, CLIN EXP RHEUMATOL, V6, P269

[22] Autologous bone-marrow transplantation for rheumatoid arthritis [J].